SCHEMBL10150102

SCHEMBL10150102

Clc1ccnc2c1CCN2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.47
NNMT P40261 2/20 0.44
HTR2C P28335 3/20 0.39
HTR2A P28223 2/20 0.39
HTR2B P41595 2/20 0.39
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
AXL P30530 1/20 0.34
PRKCI P41743 1/20 0.34
HTT P42858 1/20 0.34
PTK2B Q14289 1/20 0.34
AKT1S1 Q96B36 3/20 0.34
KDR P35968 1/20 0.33
LRRK2 Q5S007 1/20 0.33
PNMT P11086 1/20 0.32
DAO P14920 1/20 0.32
DRD1 P21728 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1330038 0.88 UHRF1 (0.41) NOTUMNNMTHTR2CHTR2AHTR2B
SCHEMBL13991574 0.75 PARP10 (0.42) NOTUMNNMTHTR2CHTR2AHTR2B
SCHEMBL13138806 0.75 PARP1 (0.42) NOTUMNNMTAKT1S1KDRLRRK2
SCHEMBL580706 0.75 NNMT (0.37) NOTUMNNMTDRD1
SCHEMBL10279840 0.75 NNMT (0.37) NOTUMNNMTKDRLRRK2DRD1
SCHEMBL795352 0.75 NNMT (0.44) NNMTHTR2CHTR2AHTR2BPARP10
Hydrochloric Acid SCHEMBL31330403 0.75 NNMT (0.37) NOTUMNNMTPARP10PARP11AKT1S1
SCHEMBL3009275 0.75 DAO (0.37) DAO
SCHEMBL24288319 0.72 NNMT (0.38) NNMTPARP10PARP11LRRK2DRD1
SCHEMBL14510804 0.72 HTR2A (0.35) NNMTHTR2CHTR2AHTR2BLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
CN-116283916-B Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2024-06-11 CN disclosed
CN-116283916-A Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2023-06-23 CN disclosed
CN-112457295-B Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof 中国科学院上海药物研究所 2022-07-26 CN disclosed
WO-2021043217-A1 COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF 中国科学院上海药物研究所 2021-03-11 WO disclosed
EP-3286166-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2020-05-13 EP disclosed
US-10221129-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2019-03-05 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed
US-9617257-B2 Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2017-04-11 US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US disclosed
US-7846941-B2 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. (US) 2010-12-07 US disclosed
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2010-10-07 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-20090247538-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2009-10-01 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
WO-2008080015-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 WO disclosed
US-7335667-B2 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors INCYTE CORPORATION (US) 2008-02-26 US disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069297-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 NOTUM 3892/4885NNMT 2190/4885HTR2C 3561/4885
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE ROCK1, ROCK2, RHOA NOTUM 2751/4885NNMT 671/4885HTR2C 3774/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 NOTUM 1197/4885NNMT 343/4885HTR2C 2571/4885
US-20090247538-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors CDK2, CDK1, OXSR1 NOTUM 4685/4885NNMT 457/4885HTR2C 364/4885
US-10221129-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H NOTUM 2229/4885NNMT 805/4885HTR2C 4597/4885
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H NOTUM 2229/4885NNMT 805/4885HTR2C 4597/4885
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 NOTUM 1477/4885NNMT 817/4885HTR2C 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.